Sunil Sharma

High Impact

Researcher

University of Arkansas for Medical Sciences

faculty

37 h-index 383 pubs 4,965 cited

Research Areas

Drug Delivery Systems Nanoparticles: synthesis and applications Immune Response and Inflammation Cancer Treatment and Pharmacology Microbial infections and disease research Semiconductor materials and devices Carbohydrate Chemistry Molecular Biology Techniques and Applications

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Sunil Sharma's research interests span multiple domains, including drug delivery systems, molecular design, and immunology.

His work has explored the self-assembly of carbohydrate-based amphiphiles for applications in pathogen inhibition and drug delivery, as detailed in a 2021 review. He has also investigated the design and synthesis of anti-inflammatory compounds, focusing on the impact of molecular structure on selective targeting, as published in 2022. In the realm of materials science, Sharma has contributed to studies on conjugated polymers for electroluminescence in quantum dot layers and the magneto-dielectric response of rare earth doped hexaferrites.

Further research includes work on long-term hepatitis B virus infection and its impact on host immunity, and a phase 1b/2 study of a combination therapy for relapsed or refractory diffuse large B-cell lymphoma. Sharma's scholarly output is marked by a high impact, evidenced by his h-index of 37 and over 4,900 citations across more than 380 publications.

Metrics

h-index: 37
Publications: 383
Citations: 4,965

Selected Publications

Unraveling the chemistry, pharmacological activities, and medicinal utilization of phloroglucinol: A comprehensive review (2025) DOI
Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+) (2025) DOI
Tuning magneto-dielectric properties of Bi-doped U-type hexaferrites via Maxwell-Wagner polarization engineering (2025) DOI
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer (2025) DOI
A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer (2025) DOI
Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures (2025) DOI
Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors. (2025) DOI
Efficient synthesis of coumarin based triazole linked O-glycoconjugates as new bio-active glycohybrids (2025) DOI
Improved Detection Rate of Breast Cancer Using 3D Magnetic Resonance Imaging (2024) DOI
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update. (2024) DOI
A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. (2024) DOI
Efficient synthesis and in-silico studies of pyrano[3,2-c]pyrones based glycohybrids (2024) DOI
Stimuli-responsive azo-functionalized non-ionic amphiphiles for controlled drug delivery applications (2024) DOI
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer (2024) DOI
Polatuzumab vedotin, venetoclax, and an <scp>anti‐CD20</scp> monoclonal antibody in relapsed/refractory B‐cell <scp>non‐Hodgkin</scp> lymphoma (2024) DOI